share_log

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Alterity Therapeutics | 6-K：外國發行人報告
美股SEC公告 ·  04/15 08:03
Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced the application for quotation of securities on April 15, 2024. The company, listed under the ticker ATH on the ASX, is seeking to quote a total of 285,087,715 options expiring on August 31, 2026. These options, identified with the security code ATHO, were issued as part of a transaction previously announced on February 23, 2024. The options are being issued without cash consideration; instead, they are attached to placement shares issued per the placement announcement made earlier in February. Following the quotation, Alterity Therapeutics' issued capital will include over 5 billion ordinary fully paid shares and a variety of option classes with different expiration dates and exercise prices.
Alterity Therapeutics Limited, a development stage enterprise, has announced the application for quotation of securities on April 15, 2024. The company, listed under the ticker ATH on the ASX, is seeking to quote a total of 285,087,715 options expiring on August 31, 2026. These options, identified with the security code ATHO, were issued as part of a transaction previously announced on February 23, 2024. The options are being issued without cash consideration; instead, they are attached to placement shares issued per the placement announcement made earlier in February. Following the quotation, Alterity Therapeutics' issued capital will include over 5 billion ordinary fully paid shares and a variety of option classes with different expiration dates and exercise prices.
處於發展階段的企業Alterity Therapeutics Limited已於2024年4月15日宣佈了證券報價申請。該公司在澳大利亞證券交易所上市，股票代碼爲ATH，正在尋求對將於2026年8月31日到期的總共285,087,715份期權進行報價。這些期權以安全代碼ATHO標識，是先前於2024年2月23日宣佈的交易的一部分發行的。這些期權是在沒有現金對價的情況下發行的；相反，它們附在根據2月初發布的配售公告發行的配售股票上。報價後，Alterity Therapeutics的已發行資本將包括超過50億股全額支付的普通股以及具有不同到期日和行使價的各種期權類別。
處於發展階段的企業Alterity Therapeutics Limited已於2024年4月15日宣佈了證券報價申請。該公司在澳大利亞證券交易所上市，股票代碼爲ATH，正在尋求對將於2026年8月31日到期的總共285,087,715份期權進行報價。這些期權以安全代碼ATHO標識，是先前於2024年2月23日宣佈的交易的一部分發行的。這些期權是在沒有現金對價的情況下發行的；相反，它們附在根據2月初發布的配售公告發行的配售股票上。報價後，Alterity Therapeutics的已發行資本將包括超過50億股全額支付的普通股以及具有不同到期日和行使價的各種期權類別。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息